Arthur M. “Buzz” Brown, M.D., Ph.D. is ChanTest’s founder, President & CEO, and an Adjunct Professor of Physiology and Biophysics at Case Western Reserve University, School of Medicine. He is a trained cardiologist and physiologist with more than 30 years of experience in ion channels and their relationship to human disease and has published extensively in peer-reviewed journals. Dr. Brown has established world-leading Physiology department at University of Texas Medical Branch, Baylor College of Medicine and Case Western Reserve University.

Major contributions from his research laboratories to the field of ion channels include:

1. invention of ion-selective liquid exchanger microelectrodes;
2. description of membrane–delimited G protein effects on ion channels;
3. identification of the pore of voltage-gated and inwardly rectifying potassium channels;
4. specification of hERG potassium channel as lethal target for non-cardiac drugs, e.g., Seldane, Propulsid, etc.; and
5. discovery of drug-induced block of hERG trafficking as cause of arrhythmias.

Dr. Brown’s honors include the following:

• Established Investigator of the American Heart Association
• Javits Neuroscience Investigator Award
• The Harry B van Dyke Awards for Excellence in Medical Research (Pharmacology), Columbia University College of Physicians and Surgeons
• American Physiological Society Water B. Cannon Lecturer
• Recipient of American Heart Association Basic Research Prize
• Recipient of Louis and Artur Lucian Award for Research in Circulatory Diseases
• First Robert M. Berne Distinguished Lecturer of the American Physiological Society Cardiovascular Section
• Newton-Abraham Visiting Professor in Medical, Biological and Chemical Sciences, (MA Honors), University of Oxford, England

Dr. Brown is currently a collaborator with the US Federal Drug Administration (FDA) on cardiac safety issues. He holds nine patents on ion channel pharmacology, therapeutics and devices.

Chris Mathes, Ph.D., M.B.A. is the Chief Commercial Officer (CCO) since September 2012 and over sees sales, marketing and customer relations at ChanTest. Previously, Dr. Mathes was involved in the development, testing and marketing of novel high-throughput electrophysiology systems. Overall, Dr. Mathes has more than 20 years of experience with the patch clamp technique and ion channel research. Mathes earned a B.S. in Biology (with departmental honors) from Stanford University. He received his Ph.D. degree in Neuroscience from the University of California, Los Angeles. More recently, Mathes earned an Executive M.B.A. degree from Rutgers University (Beta Gamma Sigma).

Jessica Brimecombe, Ph.D. is Senior Director, Laboratory Operations and Cardiac Safety Services. She also serves as a member of the Quality Team to provide improved safety testing performance and profitability. Dr. Brimecombe joined the company in 2003 and has served ChanTest as Study Director and head of Quality Control. Previously, she was a scientist at Neurocrine Biosciences in San Diego, CA. She holds a B.A. in Psychology from Hiram College and a Ph.D. in Neurobiology from the University of Pittsburgh.

Emir Duzic, Ph.D. joined ChanTest, Corp. in 2010 and serves as Senior Director, Discovery Services. Dr. Duzic has more than18 years of drug discovery experience, largely focused on G protein-coupled receptors (GPCRs). Dr. Duzic was previously associate director of Molecular & Cellular Pharmacology at Cephalon, Inc., where he was a member of the Senior Research Management Team and was responsible for directing HTS targeting GPCRs and in vitro pharmacology. Prior to that, he was associate director of Cellular Biology at Millennium Pharmaceuticals, head of Receptor Pharmacology at OSI Pharmaceuticals, formerly Cadus Pharmaceuticals, and senior scientist at Wyeth Research, formerly Lederle Laboratories. He is co-author of more than 35 peer-reviewed publications and co-inventor on 5 patents. He is member of ASPET, SLAS, AAAS and NYAS. Dr. Duzic received his Ph.D. in Experimental Pharmacology from the University of Sarajevo, Bosnia and Herzegovina and was a NIH Fogarty Postdoctoral Fellow at the Harvard Medical School.